Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 8/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.47 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103767 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL1108656 | 0.82 | CHRNB2 (0.58) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL31108110 | 0.79 | CHRNB2 (0.52) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL31108103 | 0.79 | CHRNB2 (0.52) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL22330323 | 0.79 | CHRNB2 (0.55) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL26151691 | 0.79 | MAP3K12 (0.40) | — | |
| SCHEMBL25888993 | 0.79 | CHRNB2 (0.57) | CHRNB2CHRNA4HSD11B1CHRNB4CHRNA3 | |
| Hydrochloric Acid SCHEMBL5043519 | 0.78 | CHRNB2 (0.58) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 | |
| SCHEMBL20249500 | 0.77 | HSD11B1 (0.46) | CHRNB2CHRNA4HSD11B1CHRNB4CHRNA3 | |
| SCHEMBL23231442 | 0.76 | CHRNB2 (0.57) | CHRNB2CHRNA4HDAC1CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7579348-B2 | Derivatives of 8-substituted xanthines | PGXHEALTH, LLC (US) | 2009-08-25 | — | — | US | disclosed |
| US-20070249598-A1 | Derivatives of 8-substituted xanthines | ADENOSINE THERAPEUTICS, LLC | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249598-A1 | Derivatives of 8-substituted xanthines | ADORA2B, ADORA2A, ADORA3 | CHRNB2 327/4885CHRNA4 479/4885HDAC1 3889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.